ACTRN12621000692831
Completed
未知
A prospective, multi-centre phase I/II trial investigating the safety and patient-reported outcomes of patients with acute uncomplicated diverticulitis through rpavirtual
Surgical Outcomes Research Centre, Royal Prince Alfred Hospital0 sites50 target enrollmentJune 7, 2021
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Acute diverticulitis
- Sponsor
- Surgical Outcomes Research Centre, Royal Prince Alfred Hospital
- Enrollment
- 50
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •To be considered for this trial, patients must:
- •1\.be diagnosed with CT\-proven acute uncomplicated diverticulitis;
- •2\.have access to a telephone, computer, or smart device with videoconferencing capabilities;
- •3\.reside within the SLHD catchment area during the time of admission to iCAD.
Exclusion Criteria
- •The following patient scenarios are excluded:
- •1\.generalised peritonitis
- •2\.temperature \> 38°C
- •3\.heart rate \> 100, or evidence of haemodynamic instability
- •4\.white cell count (WCC) \>20, C reactive protein (CRP) \>150, or acute renal impairment
- •5\.other signs or symptoms concerning for systemic sepsis
- •6\.pregnancy
- •7\.immunosuppressed
- •8\.cognitive impairment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed aggressive LymphomaC83.3Diffuse large B-cell lymphomaDRKS00023793niversitätsmedizin der Johannes Gutenberg-Universität Mainz26
Active, not recruiting
Phase 1
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma.Malignant B-cell lymphomaMedDRA version: 21.0Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-002373-59-DEniversity Medical Center of the Johannes Gutenberg University Mainz64
Active, not recruiting
Not Applicable
A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple MyelomaMultiple Myeloma (Salmon-Durie stage II or III, Relapsed or refractory disease after failure of two or more treatment regimens)MedDRA version: 8.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2006-002675-41-DEniversitaetsklinikum Schleswig-Holstein
Active, not recruiting
Phase 1
A study to investigate the safety and antiemetic efficacy of 2 agents: Akynzeo® plus dexamethasone in patients receiving simultaneously radiotherapy and chemotherapy with weekly cisplatin for at least five weeks.Eligible patients will have a diagnosis of cervical cancer, and be scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of = 40 mg/m2 for at least five weeks. Patients must be naïve to both radiotherapy and chemotherapy.Therapeutic area: Not possible to specifyEUCTR2017-004031-37-DKDepartment of oncology, Odense University Hospital80
Active, not recruiting
Phase 1
Clinical trial conducted to evaluate the effectiveness of a combination of drugs called venetoclax and rituximab adapted to the state of minimal residual disease in patients with untreated chronic lymphocytic leukemiaEUCTR2019-004613-14-PLPOLISH ADULT LEUKEMIA GROUP103